Basic changes in the new European guidelines for dyslipidemia management from the year 2019 are mentioned: Score risk chart changes, risk categories improvement, changes in recommended primary and secondary lipid targets. Combination of lipid modifying drugs, esp. statin with ezetimibe, event. with fenofibrate and combination statin + ezetimibe + PCSK9 inhibitors are accentuated.
New looks on HDL-ch and lipoprotein (a) are mentioned.